Case Study: The Right Ratio – Building An End-To-End DAR Strategy For ADC Success

When developing antibody-drug conjugates (ADCs), a robust drug-to-antibody ration (DAR) strategy isn’t just nice to have — it's mission-critical.

In this case study, we supported a biopharma team in building an end-to-end DAR strategy that went far beyond reporting an average value. Our approach delivered a precise, quantitative distribution profile of individual DAR species (e.g., DAR 0, 2, 4, 6), mapped conjugation sites to understand payload attachment patterns, and established a framework that supported the program from IND submission through release testing setup and long-term quality control.